Add to ORKGThe candidate malaria vaccine RTS,S/AS01 is currently in phase 3 trials in multiple sites across sub-Saharan Africa [1,2]. Efficacy against clinical malaria over one year of follow-up was 55.8 % (97.5 % confidence interval (CI): 50.6 % to 60.4%) in children 5- to 17-months old [1] but was significantly lower in infants 6- to 12-weeks old (31.3%, 97.5 % CI: 23.6 % to 38.3%) [2]. Vaccine-induced geometric mean anti-circumsporozoite protein (CSP) anti-body titres following the third dose in the 6- to 12-week cohort was 209 ELISA units/ml (EU/mL) (95 % CI: 197 to 222) [2] significantly lower than in the 5- to 17-month co-hort (621 EU/mL, 95 % CI: 592 to 652) [1]. Two potential reasons for the lower observed vaccine efficacy in the 6- to 12-week...
BACKGROUND: The efficacy and safety of the RTS,S/AS01 candidate malaria vaccine during 18 months of ...
Background: The pre-erythrocytic malaria vaccine RTS,S/AS02A has shown to confer protection against ...
Background: RTS,S/AS01 E, the most advanced malaria vaccine confers partial immunity. The vaccine-in...
BACKGROUND: The RTS,S/AS01 malaria vaccine targets the circumsporozoite protein, ind...
Background:A malaria vaccine could be an important addition to current control strategies. We report...
SummaryBackgroundThe RTS,S/AS01 malaria vaccine targets the circumsporozoite protein, inducing antib...
Malaria remains an important cause of morbidity and mortality among children in sub-Saharan Africa d...
The nature of protective immune responses elicited by immunization with the candidate malaria vaccin...
BACKGROUND: RTS,S/AS01E is the lead candidate malaria vaccine. We recently showed efficacy against c...
BACKGROUND: The candidate malaria vaccine RTS,S/AS01E has entered phase 3 trials, but data on long-t...
BACKGROUND: An ongoing phase 3 study of the efficacy, safety, and immunogenicity of candidate malari...
Background The RTS,S/AS01 malaria vaccine candidate is being evaluated for implementation. Methods W...
Background An ongoing phase 3 study of the efficacy, safety, and immunogenicity of candidate malaria...
Partial protective efficacy lasting up to 43 months after vaccination with the RTS,S malaria vaccine...
BACKGROUND: Plasmodium falciparum malaria is a pressing global health problem. A previous study of t...
BACKGROUND: The efficacy and safety of the RTS,S/AS01 candidate malaria vaccine during 18 months of ...
Background: The pre-erythrocytic malaria vaccine RTS,S/AS02A has shown to confer protection against ...
Background: RTS,S/AS01 E, the most advanced malaria vaccine confers partial immunity. The vaccine-in...
BACKGROUND: The RTS,S/AS01 malaria vaccine targets the circumsporozoite protein, ind...
Background:A malaria vaccine could be an important addition to current control strategies. We report...
SummaryBackgroundThe RTS,S/AS01 malaria vaccine targets the circumsporozoite protein, inducing antib...
Malaria remains an important cause of morbidity and mortality among children in sub-Saharan Africa d...
The nature of protective immune responses elicited by immunization with the candidate malaria vaccin...
BACKGROUND: RTS,S/AS01E is the lead candidate malaria vaccine. We recently showed efficacy against c...
BACKGROUND: The candidate malaria vaccine RTS,S/AS01E has entered phase 3 trials, but data on long-t...
BACKGROUND: An ongoing phase 3 study of the efficacy, safety, and immunogenicity of candidate malari...
Background The RTS,S/AS01 malaria vaccine candidate is being evaluated for implementation. Methods W...
Background An ongoing phase 3 study of the efficacy, safety, and immunogenicity of candidate malaria...
Partial protective efficacy lasting up to 43 months after vaccination with the RTS,S malaria vaccine...
BACKGROUND: Plasmodium falciparum malaria is a pressing global health problem. A previous study of t...
BACKGROUND: The efficacy and safety of the RTS,S/AS01 candidate malaria vaccine during 18 months of ...
Background: The pre-erythrocytic malaria vaccine RTS,S/AS02A has shown to confer protection against ...
Background: RTS,S/AS01 E, the most advanced malaria vaccine confers partial immunity. The vaccine-in...